Tumour Versus Germline BRCA Testing in Ovarian Cancer: A Single-Site Institution Experience in the United Kingdom
Open Access
- 19 March 2021
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 11 (3) , 547
Abstract
The aim of this audit was to evaluate the usefulness and serviceability of testing for pathogenic mutations in BRCA1 or BRCA2 (BRCA1/2) genes in ovarian cancer (OC) patients. One hundred and thirty-five patients with more common histological sub-types of OC were retrospectively identified between 2011 and 2019. The fail rate of the molecular analysis was 7.4% (10/135). One hundred and twenty-five records were evaluated: 99 (79.2%) patients had wild-type BRCA (both somatic and germline); tumour BRCA1/2 (tBRCA1/2) pathogenic mutations were found in 20 (16%) patients with distribution between BRCA1 and BRCA2 being 40% and 60%, respectively; 13 (10.4%) patients with pathogenic variants had germline mutations; and tBRCA1/2 with variant of unknown significance (VUS), in the absence of pathogenic BRCA1 or BRCA2 variants, was detected in 6 (4.8%) patients. Our data show that expanding the molecular service to the routine first-tumour testing for patients with OC will potentially increase the detection rate of BRCA mutations, thereby providing early benefits of PARP inhibitors therapy. The tumour testing service should continue to be offered to newly diagnosed patients with high-grade epithelial cancers, including high-grade serous carcinoma, but also with carcinosarcomas and poorly-differentiated metastatic adenocarcinomas of unknown origin.Keywords
This publication has 29 references indexed in Scilit:
- BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significanceAnnals of Oncology, 2015
- Correction: Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer CasesPLOS ONE, 2013
- Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer CasesPLOS ONE, 2013
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian CancerJAMA, 2012
- Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian CarcinomasJournal of Clinical Oncology, 2011
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying TheoryAmerican Journal of Surgical Pathology, 2010
- Resistance to therapy caused by intragenic deletion in BRCA2Nature, 2008
- Identification of the breast cancer susceptibility gene BRCA2Nature, 1995